natgillin/translations-raw huggingface dataset:
This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially “sodiumfree”. 
Ovaj lijek sadrži manje od 1 mmol natrija (23 mg) po dozi, tj. u osnovi ne sadrži natrij.
Men: 
Muškarci:
Adverse reactions are listed in Table 3 below. 
Nuspojave su navedene u Tablici 3 dalje u tekstu.
White lyophilisate and clear, colourless solvent. 
Bijeli liofilizat i bistro, bezbojno otapalo.
15 Pinch the selected injection site and fully insert the needle at a 45° to 90° angle with a quick, firm action. 
15. Uhvatite nabor kože na odabranom mjestu injiciranja te brzim i odlučnim pokretom ubodite iglu cijelom dužinom pod kutom od 45° do 90°.
(8.7 mmol/l), - shortened overall survival and increased deaths attributed to disease progression at 4 months in patients with metastatic breast cancer receiving chemotherapy when administered to target a haemoglobin of 12-14 g/dl (7.5-8.7 mmol/l), - increased risk of death when administered to target a haemoglobin of 12 g/dl (7.5 mmol/l) in patients with active malignant disease receiving neither chemotherapy nor radiation therapy. 
- skraćuju ukupno preživljenje i povećava smrtnost povezanu s napredovanjem bolesti nakon četiri mjeseca u bolesnika s metastatskim rakom dojke koji primaju kemoterapiju, kada se daju radi postizanja ciljne razine hemoglobina od 12 - 14 g/dl (7,5 - 8,7 mmol/l), povećavaju rizik od smrti kada se daju radi postizanja ciljne razine hemoglobina od 12 g/dl (7,5 mmol/l) u bolesnika s aktivnom zloćudnom bolesti koji se ne liječe ni kemoterapijom ni radioterapijom.
· Dispose of the rubber cap in a puncture-resistant or sharps container immediately. 
Gumeni zatvarač odmah odložite u neprobojni spremnik ili spremnik za oštre predmete.
Each pack contains one vial with 50,000 IU epoetin beta, 1 ampoule with 10 ml solvent, 1 reconstitution and withdrawal device, 1 needle (21G2) and 1 disposable syringe. 
Jedno pakiranje sadrži jednu bočicu s 50 000 IU epoetina beta, 1 ampulu s 10 ml otapala, 1 nastavak za pripremu i izvlačenje pripremljene otopine, 1 iglu (21G2) i 1 štrcaljku za jednokratnu uporabu.
· Periodic Safety Update Reports 
Periodička izvješća o neškodljivosti
Adverse reactions are listed in Table 2 below. 
Nuspojave su navedene u Tablici 2 dalje u tekstu.
· Remove the needle from its blister. 
Izvadite iglu iz blistera.
· Do not try to take the syringe apart at any time. 
Nikada nemojte pokušavati rastaviti štrcaljku.
· An increase in the occurrence of blood clots has been observed. 
Primijećena je povećana pojava krvnih ugrušaka.
NeoRecormon is indicated for: - Treatment of symptomatic anaemia associated with chronic renal failure in adult and paediatric patients. 
KLINIČKI PODACI 4.1 Terapijske indikacije NeoRecormon je indiciran za: Liječenje simptomatske anemije povezane s kroničnim zatajenjem bubrega u odraslih i pedijatrijskih bolesnika.
- shortened time to tumour progression in patients with advanced head and neck cancer receiving radiation therapy when administered to target a haemoglobin of greater than 14 g/dl (8.7 mmol/l), - shortened overall survival and increased deaths attributed to disease progression at 4 months in patients with metastatic breast cancer receiving chemotherapy when administered to target a haemoglobin of 12-14 g/dl (7.5-8.7 mmol/l), - increased risk of death when administered to target a haemoglobin of 12 g/dl (7.5 mmol/l) in patients with active malignant disease receiving neither chemotherapy nor radiation therapy. 
- skraćuje ukupno preživljenje i povećava smrtnost povezanu s napredovanjem bolesti nakon četiri mjeseca u bolesnika s metastatskim rakom dojke koje primaju kemoterapiju, kada se lijekovi daju radi postizanja ciljne razine hemoglobina od 12 - 14 g/dl (7,5 - 8,7 mmol/l), povećava rizik od smrti kada se daje radi postizanja ciljne razine hemoglobina od 12 g/dl (7,5 mmol/l) u bolesnika s aktivnom zloćudnom bolesti koji se ne liječe ni kemoterapijom ni radioterapijom.
NeoRecormon 30,000 IU 1 prefilled syringe with one needle (27G1/2) or 4 pre-filled syringes with 4 needles (27G1/2). 
NeoRecormon 30 000 IU 1 napunjena štrcaljka s jednom iglom (27G1/2) ili 4 napunjene štrcaljke s 4 igle (27G1/2).
Clean the skin above the vein with an alcohol swab and let dry. 
Kožu iznad vene očistite tupferom natopljenim alkoholom i pustite da se sama osuši.
NeoRecormon 10,000 IU, 20,000 IU and 30,000 IU: Each pre-filled syringe contains 0.6 ml solution. 
NeoRecormon 10 000 IU, 20 000 IU i 30 000 IU: Svaka napunjena štrcaljka sadrži 0,6 ml otopine.
Packs of 1 vial containing 50,000 IU epoetin beta, 1 ampoule containing 10 ml solvent, 1 reconstitution and withdrawal device, 1 needle (21G2, stainless steel) and 1 disposable syringe (polypropylene and polyethylene). 
Pakiranja sadrže 1 bočicu s 50 000 IU epoetina beta, 1 ampulu s 10 ml otapala, 1 nastavak za pripremu i izvlačenje pripremljene otopine, 1 iglu (21G2, nehrđajući čelik) i 1 štrcaljku (polipropilen i polietilen) za jednokratnu uporabu.
Ask your doctor or pharmacist for advice before taking any medicine. 
Prije uzimanja bilo kakvog lijeka upitajte liječnika ili ljekarnika za savjet.
The weekly dose can be given once per week, or divided into three or seven doses per week. 
Tjedna se doza može primijeniti jednom tjedno ili podijeliti u tri ili sedam doza tjedno.
If the rate of rise in haemoglobin is greater than 2 g/dl (1.25 mmol/l) in one month or if the haemoglobin level is increasing and approaching 12 g/dl (7.45 mmol/l), the dose is to be reduced by approximately 25 %. 
Ako je brzina porasta hemoglobina unutar jednog mjeseca veća od 2 g/dl (1,25 mmol/l) ili ako vrijednost hemoglobina raste i približava se vrijednosti od 12 g/dl (7,45 mmol/l), dozu je potrebno smanjiti za otprilike 25%.
NeoRecormon in pre-filled syringe contains up to 0.3 mg phenylalanine/syringe as an excipient. 
Pomoćne tvari NeoRecormon u napunjenim štrcaljkama sadrži kao pomoćnu tvar do 0,3 mg fenilalanina po štrcaljki,
5000 IU/ ml 500 IU 1000 IU 1500 IU 2000 IU 2500 IU 3000 IU 3500 IU 4000 IU 4500 IU 5000 IU 0.1 ml 0.2 ml 0.3 ml 0.4 ml 0.5 ml 0.6 ml 0.7 ml 0.8 ml 0.9 ml 
Za svaku dozu koristite sterilne štrcaljke i igle za jednokratnu uporabu 5000 IU / ml 500 IU 1000 IU 1500 IU 2000 IU 2500 IU 3000 IU 3500 IU 4000 IU 4500 IU 5000 IU 0,1 ml 0,2 ml
NeoRecormon 500 IU, 2000 IU, 3000 IU, 4000 IU, 5000 IU and 6000 IU: Each pre-filled syringe contains 0.3 ml solution. 
NeoRecormon 500 IU, 2000 IU, 3000 IU, 4000 IU, 5000 IU i 6000 IU: Svaka napunjena štrcaljka sadrži 0,3 ml otopine.
This NeoRecormon presentation contains white lyophilisate and solvent. 
Ovaj pripravak lijeka NeoRecormon sadrži bijeli liofilizat i otapalo.
One ml solution for injection contains 33,333 IU epoetin beta. 
Jedan mililitar otopine za injekciju sadrži 33 333 IU epoetina beta.
· Take the carton with the syringe(s) and needle(s) out of the refrigerator 
Izvadite kutiju sa štrcaljkom(ama) i iglom(ama) iz hladnjaka.
What you need to know before you use NeoRecormon Do not use NeoRecormon · if you are allergic to epoetin beta or any of the other ingredients of this medicine (listed in section 6) 
● ako ste alergični na epoetin beta ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.)
Once opened, the reconstituted solution may be stored for maximum of one month at 2°C - 8°C. 
Jednom otvorena, pripremljena otopina može se čuvati najdulje mjesec dana na 2°C - 8°C
In very rare cases, neutralising anti-erythropoietin antibodies with or without pure red cell aplasia (PRCA) occurred during rHuEPO therapy. 
U vrlo rijetkim slučajevima tijekom terapije rekombinantnim humanim eritropoetinom (rHuEPO) došlo je do pojave neutralizirajućih antieritropoetinskih antitijela s ili bez izolirane aplazije crvene krvne loze (PRCA).
Misuse by healthy persons may lead to an excessive increase in packed cell volume. 
Zlouporaba u zdravih osoba može dovesti do prekomjernog povećanja hematokrita, što može dovesti do po život opasnih komplikacija kardiovaskularnog sustava.
Remove the needle and syringe from the injection site at the same angle as inserted. 
Izvucite iglu i štrcaljku iz mjesta injiciranja pod istim kutom pod kojim ste ih uveli.
If the rise in haemoglobin is greater than 2 g/dl (1.3 mmol/l) in 4 weeks, the dose should be reduced by 25 to 50 %. 
Ako je porast hemoglobina veći od 2 g/dl (1,3 mmol/l) u 4 tjedna, dozu treba smanjiti za 25 do 50%.
NeoRecormon Multidose is a lyophilisate and solvent for solution for injection. 
NeoRecormon Multidose je liofilizat i otapalo za otopinu za injekciju.
How to use NeoRecormon 
Kako primjenjivati NeoRecormon
This is because one cannot rule out a possible acceleration of progression of kidney disease with absolute certainty. 
Ne može se, naime, sa sigurnošću isključiti mogućnost ubrzanog pogoršanja bolesti bubrega.
· Instructions for Use and a package leaflet. 
Upute za uporabu i uputa o lijeku.
If, after 4 weeks of therapy, the haemoglobin value has increased by at least 1 g/dl (0.62 mmol/l), the current dose should be continued. 
Ako se nakon 4 tjedna terapije razina hemoglobina poveća za barem 1 g/dl (0,62 mmol/l), treba nastaviti liječenje istom dozom.
· Pure red cell aplasia (PRCA) caused by neutralising antibodies has been observed during erythropoietin therapy, including in isolated cases during therapy with NeoRecormon. 
Izolirana aplazija crvene krvne loze (engl. pure red cell aplasia- PRCA) uzrokovana neutralizirajućim antitijelima zabilježena je tijekom terapije eritropoetinom, uključujući, u izoliranim slučajevima, i za vrijeme terapije lijekom NeoRecormon.
Do not inject yourself unless you have received training. 
Nemojte sami injicirati NeoRecormon ako niste dobili odgovarajuću edukaciju.
3 Take one syringe out of the carton and one needle from the needle box. 
Izvadite jednu štrcaljku iz pakiranja te jednu iglu iz kutije s iglama.
This causes severe anaemia, symptoms of which would include unusual tiredness and a lack of energy. 
PRCA znači da je došlo do prestanka ili smanjene proizvodnje crvenih krvnih stanica u tijelu što uzrokuje tešku anemiju sa simptomima koji uključuju neuobičajeni umor i nedostatak energije.
INSTRUCTIONS ON USE (on the cover inside) Handling steps 
(Na poklopcu kutije iznutra) Upute za rukovanje Vidjeti uputu o lijeku
You can press a dry sterile pad over the injection site. 
Mjesto injiciranja možete pritisnuti suhom sterilnom gazom.
The initial dosage is 3 x 40 IU/kg per week. 
Početna doza iznosi 3 x 40 IU/kg tjel. mase tjedno.
Side effects which can affect any patient · Most people (very common, may affect more than 1 in 10 people) get lower levels of iron in their blood. 
U većine bolesnika (vrlo često, mogu se javiti u više od 1 na 10 osoba) dolazi do smanjenja razine željeza u krvi.
Treatment of symptomatic chemotherapy-induced anaemia in cancer patients NeoRecormon should be administered by the subcutaneous route to patients with anaemia (e.g. haemoglobin concentration ≤ 10g/dl (6.2 mmol/l). 
Bolesnicima koji boluju od anemije NeoRecormon treba davati supkutano (npr. koncentracija hemoglobina ≤ 10 g/dl (6,2 mmol/l)).
One ml solution for injection contains 13,333 IU epoetin beta. 
Jedan mililitar otopine za injekciju sadrži 13 333 IU epoetina beta.
· Serious skin rashes including Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported in association with epoetin treatment. 
Prijavljeni su ozbiljni kožni osipi, uključujući Stevens-Johnsonov sindrom i toksičnu epidermalnu nekrolizu, povezani s liječenjem epoetinom.
PHARMACEUTICAL FORM Lyophilisate and solvent for solution for injection. 
Liofilizat i otapalo za otopinu za injekciju.
If you think you have missed an injection, or been injected too little, talk to your doctor. 
Ako ste zaboravili primijeniti NeoRecormon Ako mislite da ste propustili injekciju ili da Vam je ubrizgana premala doza, obratite se svom liječniku.
The indication for NeoRecormon treatment of nephrosclerotic patients not yet undergoing dialysis should be defined individually, as a possible acceleration of progression of renal failure cannot be ruled out with certainty. 
NeoRecormon treba donijeti za svakog bolesnika pojedinačno, budući da se kod tih bolesnika ne može sa sigurnošću isključiti moguće ubrzanje progresije bubrežnog zatajenja.
Your healthcare provider will show you how to prepare and inject NeoRecormon properly before you use it for the first time. 
Prije prve uporabe NeoRecormon štrcaljke zdravstveni radnik će Vam pokazati kako pravilno pripremiti i injicirati lijek NeoRecormon.
Adverse reactions are listed in Table 1 below. 
Nuspojave su navedene u Tablici 1 dalje u tekstu.
If you have missed an injection, or injected too little, talk to your doctor. 
Ako ste zaboravili primijeniti NeoRecormon Ako ste propustili injekciju ili ubrizgali premalu dozu, obratite se svom liječniku.
Serious skin reaction including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported in association with epoetin treatment. 
Prijavljene su ozbiljne kožne reakcije, uključujući Stevens-Johnsonov sindrom (SJS) i toksičnu epidermalnu nekrolizu (TEN), povezane s liječenjem epoetinom.
Under no circumstances should more than one dose be administered per syringe; the medicinal product is for single use only. 
Jedna štrcaljka se ni u kom slučaju ne smije koristiti za davanje više od jedne doze lijeka.
12 Hold the syringe and needle tightly at the hub and carefully pull the injection needle cap away from the syringe. 
Čvrsto držite štrcaljku i iglu na mjestu gdje se spajaju (baza igle) i pažljivo povucite zatvarač igle sa štrcaljke.
This medicinal product contains less than 1 mmol sodium (23 mg) per syringe, i.e. essentially “sodium-free”. 
Ovaj lijek sadrži manje od 1 mmol natrija (23 mg) po štrcaljki, tj.zanemarive količine natrija.
Lyophilisate 
Nuspojava
How to store NeoRecormon 
Kako čuvati NeoRecormon
13 Hold the syringe with the needle pointing up. 
13. Štrcaljku držite s iglom usmjerenom prema gore.
In the case of subcutaneous administration, the weekly dose can be given as one injection per week or in divided doses three or seven times per week. 
Kod supkutane primjene, tjedna se doza može dati kao jedna injekcija tjedno ili u podijeljenim dozama tri ili sedam puta tjedno.
L-Glutamic acid, 
L- glutamatna kiselina, L-fenilalanin,
NeoRecormon can be administered through 2 manners, your doctor will decide which way is right for you: · Intravenous administration (into the vein or vein port), only to be performed by healthcare professionals. 
NeoRecormon se može primijeniti na 2 načina, a Vaš će liječnik odlučiti koji je način primjene najbolji za Vas:
The initial dose is 250 IU per injection for every 1 kg the infant weighs, three times a week. 
Početna doza iznosi 250 IU/kg tjelesne mase djeteta po injekciji, primijenjeno tri puta tjedno.
Do not use the syringe if you have dropped the syringe or if any part of the syringe appears to be damaged. 
Nemojte upotrijebiti štrcaljku ako Vam je pala ili ako bilo koji njezin dio izgleda oštećeno.
NeoRecormon 2000 IU, 3000 IU, 4000 IU, 5000 IU, 6000 IU, 10,000 IU and 20,000IU 1 prefilled syringe with one needle (27G1/2) or 6 pre-filled syringes with 6 needles (27G1/2). 
NeoRecormon 2000 IU, 3000 IU, 4000 IU,5000 IU, 6000 IU, 10 000 IU i 20 000 IU 1 napunjena štrcaljka s jednom iglom (27G1/2) ili
Consult your healthcare provider if you require further information. 
Ako Vam trebaju dodatne informacije, obratite se svom zdravstvenom radniku.
Remove the cap from the syringe. 
Uklonite zatvarač sa štrcaljke.
1 prefilled syringe with one needle (30G1/2) or 6 pre-filled syringes with 6 needles (30G1/2). 
1 napunjena štrcaljka i jedna igla (30G1/2) ili 6 napunjenih štrcaljki i 6 igala (30G1/2).
· Do not touch the plunger while inserting the needle into the skin · Do not insert the needle through clothing. 
Nemojte dodirivati klip dok ubadate iglu u kožu.
- In the solvent: benzyl alcohol and benzalkonium chloride as preservatives and water for injections. 
U otapalu: konzervansi benzilni alkohol i benzalkonijev klorid i voda za injekcije.
Severe cutaneous adverse reactions (SCARs) including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), which can be life-threatening or fatal, have been reported in association with epoetin treatment (see section 4.8). 
Prijavljene su teške kožne nuspojave (SCAR), uključujući Stevens-Johnsonov sindrom (SJS) i toksičnu epidermalnu nekrolizu (TEN), povezane s liječenjem epoetinom, koje mogu biti opasne po život ili smrtonosne (vidjeti dio 4.8).
If you have high or rising potassium levels your doctor may reconsider your treatment · your blood platelet count. 
Poveća li Vam se razina kalija, liječnik bi mogao ponovno razmotriti Vaše liječenje.
One ml solution for injection contains 16,667 IU epoetin beta. 
Jedan mililitar otopine za injekciju sadrži 16 667 IU epoetina beta.
Occlusion of the dialysis system is possible if heparinisation is not optimum. 
Neodgovarajuća heparinizacija može dovesti do začepljenja dijaliznog sistema.
In chronic renal failure patients there may be a moderate dose-dependent rise in the platelet count within the normal range during treatment with NeoRecormon, especially after intravenous administration. 
Kod bolesnika s kroničnim zatajenjem bubrega tijekom liječenja lijekom NeoRecormon može doći do umjerenog, o dozi ovisnog porasta broja trombocita unutar normalnih granica, poglavito nakon intravenske primjene, koje se povlači u nastavku liječenja.
Severe cutaneous adverse reactions (SCARs) including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), which can be life-threatening or fatal, have been reported in association with epoetin treatment (see section 4.4) 
Prijavljene su teške kožne nuspojave (SCAR), uključujući Stevens-Johnsonov sindrom (SJS) i toksičnu epidermalnu nekrolizu (TEN), povezane s liječenjem epoetinom, koje mogu biti opasne po život ili smrtonosne (vidjeti dio 4.4.).
NeoRecormon dosing 
NeoRecormon.
Adverse reactions attributed to the treatment with NeoRecormon in controlled clinical trials in patients in an autologous blood predonation programme System organ class 
Često Tablica 3: Nuspojave pripisane liječenju lijekom NeoRecormon u kontroliranim kliničkim ispitivanjima u bolesnika u programu predonacije autologne krvi
NeoRecormon Multidose is supplied as a lyophilisate for solution for injection in vials. 
NeoRecormon Multidose dolazi u obliku liofilizata za otopinu za injekciju u bočicama.
Adverse reactions attributed to the treatment with NeoRecormon in controlled clinical trials in cancer patients System organ class 
Tablica 2: Nuspojave pripisane liječenju lijekom NeoRecormon u kontroliranim kliničkim ispitivanjima u bolesnika s rakom
The dosage must be determined by the surgical team individually for each patient as a function of the required amount of pre-donated blood and the endogenous red cell reserve: The required amount of pre-donated blood depends on the anticipated blood loss, use of blood conserving procedures and the physical condition of the patient. 
Dozu treba odrediti kirurški tim pojedinačno za svakog bolesnika, ovisno o potrebnoj količini predonirane krvi i endogenoj rezervi eritrocita pojedinog bolesnika:
· 1 dry sterile pad. 
● 1 suha sterilna gaza
The weekly dose can be given as one injection per week or in divided doses 3 to 7 times per week. 
Tjedna se doza može dati kao jedna injekcija tjedno ili u podijeljenim dozama 3 do7 puta tjedno.
Adverse reactions attributed to the treatment with NeoRecormon in controlled clinical trials in CKD patients System organ class 
Tablica 1: Nuspojave pripisane liječenju lijekom NeoRecormon u kontroliranim kliničkim ispitivanjima u bolesnika s kroničnim zatajenjem bubrega Organski sustav
NeoRecormon 5000 IU solution for injection in pre-filled syringe One pre-filled syringe with 0.3 ml solution for injection contains 5000 international units (IU) corresponding to 41.5 micrograms epoetin beta* (recombinant human erythropoietin). 
NeoRecormon 5000 IU otopina za injekciju u napunjenoj štrcaljki Jedna napunjena štrcaljka s 0,3 ml otopine za injekciju sadrži 5000 internacionalnih jedinica (IU) što odgovara 41,5 mikrograma epoetina beta* (rekombinantnog ljudskog eritropoetina).
The ability to donate blood depends predominantly on the patient's blood volume and baseline PCV. 
Sposobnost bolesnika za davanje krvi, u prvom redu, ovisi o njegovom volumenu krvi te početnoj vrijednosti hematokrita.
· Very rarely (may affect up to 1 in 10,000 people), patient experienced flu-like symptoms, especially when they just started treatment. 
Vrlo rijetko (mogu se javiti u do 1 na 10 000 osoba) se u bolesnika javljaju simptomi nalik gripi, posebno na samom početku liječenja.
One ml solution for injection contains 6667 IU epoetin beta. 
Jedan mililitar otopine za injekciju sadrži 6667 IU epoetina beta.
Preparing for injection 
Primjena intravenske injekcije
Traceability of NeoRecormon 
Sljedivost lijeka NeoRecormon
Throw away the needle cap in a sharps container immediately. 
Zatvarač igle odmah odložite u spremnik za oštre predmete.
One ml solution for injection contains 1667 IU epoetin beta. 
Jedan mililitar otopine za injekciju sadrži 1667 IU epoetina beta.
- Intravenous administration: The initial dosage is 3 x 40 IU/kg per week. 
- Intravenska primjena: Početna doza iznosi 3 x 40 IU/kg tjel. mase tjedno.
haemoglobin concentration ≤ 10g/dl (6.2 mmol/l). 
14 g/dl (8,7 mmol/l),
· Treating anaemia with related symptoms in adult cancer patients receiving chemotherapy · Treating people donating their own blood before surgery. 
Liječenje bolesnika koji doniraju vlastitu krv prije operacije.
One ml solution for injection contains 50,000 IU epoetin beta. 
Jedan mililitar otopine za injekciju sadrži 50 000 IU epoetina beta.
NeoRecormon 30,000 IU solution for injection in pre-filled syringe One pre-filled syringe with 0.6 ml solution for injection contains 30,000 international units (IU) corresponding to 250 micrograms epoetin beta* (recombinant human erythropoietin). 
NeoRecormon 30 000 IU otopina za injekciju u napunjenoj štrcaljki Jedna napunjena štrcaljka s 0,6 ml otopine za injekciju sadrži 30 000 internacionalnih jedinica (IU) što odgovara 250 mikrograma epoetina beta* (rekombinantnog ljudskog eritropoetina).
Hypertension Hypertensive crisis 
Poremećaji krvožilnog sustava Hipertenzija
Phenylalanine (up to 0.3 mg/syringe) 
fenilalanin (do 0,3 mg/štrcaljki) natrij (manje od 1 mmol/štrcaljki)
Additional side effects in adults receiving chemotherapy for cancer · Increase in blood pressure and headache may occasionally occur. 
Povremeno se mogu pojaviti povišeni krvni tlak i glavobolja.
In isolated cases, neutralising anti erythropoietin antibody-mediated pure red cell aplasia (PRCA) associated with NeoRecormon therapy has been reported. 
U izoliranim je slučajevima uz terapiju lijekom NeoRecormon zabilježena izolirana aplazija crvene krvne loze (PRCA) uzrokovana neutralizirajućim antieritropoetinskim antitijelima.
In preterm infants a potential risk of erythropoietin to cause retinopathy could not be excluded, therefore caution should be exercised and the decision to treat a preterm infant should be balanced against the potential benefit and risk of this treatment and available alternative options. 
Odluku o liječenju nedonoščeta treba donijeti uzimajući u obzir moguću korist naspram rizika takvog liječenja te dostupnost zamjenskog liječenja.
One ml solution for injection contains 20,000 IU epoetin beta. 
Jedan mililitar otopine za injekciju sadrži 20 000 IU epoetina beta.
NeoRecormon Multidose 50,000 IU lyophilisate and solvent for solution for injection Epoetin beta 
NeoRecormon Multidose 50 000 IU liofilizat i otapalo za otopinu za injekciju epoetin beta
One ml solution for injection contains 10,000 IU epoetin beta. 
Jedan mililitar otopine za injekciju sadrži 10 000 IU epoetina beta.
INFORMATION IN BRAILLE neorecormon 2000 IU 
neorecormon 2000 IU
INFORMATION IN BRAILLE neorecormon 20.000 IU 
neorecormon 20 000 IU
The reconstituted product is a colourless, clear to slightly opalescent solution. 
Pripremljeni lijek je bezbojna, bistra do blago opalescentna otopina.